"Designing Growth Strategies is in our DNA"
Nonalcoholic steatohepatitis (NASH) is a type of liver inflammation caused due to accumulation of fat in the liver. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) demonstrate very few or no symptoms at the initial stages. Some symptoms such as fatigue, weight loss, general weakness and ache in the upper right part of belly are observed at later stages. The exact cause of NASH is unknown, but some of the common causes include obesity, type 2 diabetes, high cholesterol & triglycerides and metabolic syndrome.
Currently, there are no treatments available of non-alcoholic steatohepatitis (NASH). The first line of treatment is weight loss through a combination of a healthy diet and exercise. In February 2019, Intercept Pharmaceuticals, Inc., announced positive topline results from pivotal phase 3 regenerate study of obeticholic acid in patients with liver fibrosis due to NASH.
Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for non-alcoholic steatohepatitis (NASH) treatment. For instance, Seladelpar, which is being studied by CymaBay Therapeutics, Inc., is currently in phase-2 clinical trials for the study to evaluate seladelpar in subjects with nonalcoholic steatohepatitis (NASH)
To know how our report can help streamline your business, Speak to Analyst
At present around 50% of the pipeline candidates for non-alcoholic steatohepatitis (NASH) treatment are in the phase-1 and phase-2 stage. More than half of the studies are sponsored by industry.
The report on ‘Non-alcoholic Steatohepatitis (NASH) Treatment – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for non-alcoholic steatohepatitis (NASH) treatment. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, and description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for non-alcoholic steatohepatitis (NASH) treatment.
The report on ‘Non-alcoholic Steatohepatitis (NASH) Treatment – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry